Ocumension Therapeutics (HK:1477)
:1477
Want to see HK:1477 full AI Analyst Report?
1477 Stock Chart & Stats
HK$7.55
-HK$0.01(-0.25%)
At close: 4:00 PM EST
HK$7.55
-HK$0.01(-0.25%)
Day’s Range― - ―
52-Week RangeHK$4.74 - HK$12.23
Previous CloseN/A
Volume1.11M
Average Volume (3M)3.41M
Market Cap
HK$3.99B
Enterprise ValueHK$3.10B
Total Cash (Recent Filing)HK$547.50M
Total Debt (Recent Filing)HK$187.62M
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Aug 20, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding836,331,900
10 Day Avg. Volume1,456,522
30 Day Avg. Volume3,406,832
Financial Highlights & Ratios
PEG Ratio0.68
Price to Book (P/B)1.43
Price to Sales (P/S)6.54
P/FCF Ratio-14.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$10.16Price Target Upside34.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.01
Revenue Forecast (FY)HK$1.10B
Bulls Say, Bears Say
Bulls Say
Accelerating Revenue GrowthSustained ~44% top-line growth signals durable commercial traction in ophthalmology markets. Persistent revenue expansion supports scale economies, funds incremental operating expenses, and, if maintained, materially improves the odds of reaching sustainable profitability without relying solely on non-operating fixes.
Healthy Gross MarginsA ~44% gross margin indicates structurally favorable product economics and pricing power in core ophthalmic therapies. Strong unit economics provide room to invest in sales and R&D while preserving operating leverage, improving the company's path to positive EBIT as revenue scales.
Conservative Balance SheetVery low leverage grants financial flexibility across clinical and commercialization cycles, lowering default and interest risks. A strong equity base supports continued investment and M&A optionality, reducing near-term refinancing pressure while management executes on growth initiatives.
Bears Say
Negative Operating & Free Cash FlowConsistent negative operating and free cash flow forces the company to rely on external financing, raising dilution and refinancing risk. Persistent cash burn constrains reinvestment flexibility, making long-term plans sensitive to capital markets and increasing execution risk if cash needs spike.
Ongoing Net Losses / Negative ROEDespite revenue gains, sustained net losses and negative ROE signal capital inefficiency and delayed shareholder value creation. Continued unprofitability limits the firm's ability to self-fund growth and may reduce investor appetite for additional equity at favorable terms.
Reliance On External CapitalOngoing dependence on outside financing increases vulnerability to market tightening and potential dilution. Even with moderating burn, strategic initiatives are conditional on capital access, which can delay product rollouts or scale-up if funding costs rise or market windows close.
Ocumension Therapeutics News
1477 FAQ
What was Ocumension Therapeutics’s price range in the past 12 months?
Ocumension Therapeutics lowest stock price was HK$4.74 and its highest was HK$12.23 in the past 12 months.
What is Ocumension Therapeutics’s market cap?
Ocumension Therapeutics’s market cap is HK$3.99B.
When is Ocumension Therapeutics’s upcoming earnings report date?
Ocumension Therapeutics’s upcoming earnings report date is Aug 20, 2026 which is in 62 days.
How were Ocumension Therapeutics’s earnings last quarter?
Ocumension Therapeutics released its earnings results on Mar 26, 2026. The company reported -HK$0.046 earnings per share for the quarter, beating the consensus estimate of -HK$0.081 by HK$0.035.
Is Ocumension Therapeutics overvalued?
According to Wall Street analysts Ocumension Therapeutics’s price is currently Undervalued.
Does Ocumension Therapeutics pay dividends?
Ocumension Therapeutics does not currently pay dividends.
What is Ocumension Therapeutics’s EPS estimate?
Ocumension Therapeutics’s EPS estimate is -0.03.
How many shares outstanding does Ocumension Therapeutics have?
Ocumension Therapeutics has 836,331,900 shares outstanding.
What happened to Ocumension Therapeutics’s price movement after its last earnings report?
Ocumension Therapeutics reported an EPS of -HK$0.046 in its last earnings report, beating expectations of -HK$0.081. Following the earnings report the stock price went down -0.996%.
Which hedge fund is a major shareholder of Ocumension Therapeutics?
Currently, no hedge funds are holding shares in HK:1477
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ocumension Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
29.56%
12-Months-Change
Fundamentals
Return on Equity
-4.33%
Trailing 12-Months
Asset Growth
7.75%
Trailing 12-Months
Company Description
Ocumension Therapeutics
Based in the People's Republic of China, Ocumension Therapeutics functions as a dedicated ophthalmic pharmaceutical platform. This company, along with its subsidiaries, is committed to the research, progression, and market introduction of therapeutic solutions for individuals with various eye conditions. Its extensive product offerings target treatments for disorders such as blepharitis, infectious and allergic conjunctivitis, dry eye syndrome, cataracts, glaucoma, ocular hypertension, post-surgical inflammation, uveitis, retinitis pigmentosa, age-related macular degeneration, corneal graft rejection, myopia, and optic neuritis. By December 31, 2021, Ocumension Therapeutics boasted a pipeline of 20 drug assets. The company, founded in 2017, maintains its headquarters in Suzhou, China.
1477 Stock 12 Month Forecast
Average Price Target
HK$10.16
▲(34.57% Upside)
Technical Analysis
Jiangsu Recbio Technology Co., Ltd. Class H
―
Mabpharm Limited
―
Zhaoke Ophthalmology Ltd.
―
Transcenta Holding Limited
―
Shandong Boan Biotechnology Company., Limited. Class H
―
Options Prices
Currently, No data available
---